Meesho, Lenskart Seen Drawing FTSE-Linked Inflows in September Review
FTSE’s Emerging Markets All Cap review is expected to add Meesho, Lenskart, Groww, Pine Labs and Urban Company. Brokerage estimates put potential passive inflows at $75.9 million for Meesho and $71.1 million for Lenskart, while Biocon faces estimated outflows of $20 million.
What happened
FTSE’s September 2026 Emerging Markets All Cap review adds Indian companies including Meesho, Lenskart, Groww and Pine Labs. Brokerages estimate passive-fund
Key facts
- 10 Indian companies included
- Meesho estimated inflows: $75.9 million
- Lenskart estimated inflows: $71.1 million
- Groww estimated inflows: $56.2 million
- Pine Labs estimated inflows: $38 million
- Urban Company estimated inflows: $42 million
- Biocon estimated outflows: $20 million
Why this matters
The expected index additions strengthen the strategic currency of newly listed consumer-tech platforms, potentially improving their capacity for acquisitions, partnerships and expansion financing.
What to watch
- FTSE’s final September review announcement, effective date and published investability-adjusted index weights.
- Actual foreign-investor accessibility, free-float calculations and any foreign-ownership-limit constraints.
- Passive-flow estimates relative to each stock’s average daily value traded and derivatives/open-interest activity.
- Pre-rebalance block deals, promoter/anchor sales, lock-up expiries and changes in institutional ownership.
- Management guidance on profitability, customer growth, take rate, advertising monetization and cash burn after listing.
- Broader risk appetite for Indian IPOs and consumer-internet equities, including INR moves and EM fund flows.
- Biocon’s realized rebalance outflow and price/volume behavior as a gauge of index-arbitrage intensity.
- Accumulate shares selectively before the FTSE effective date only where expected passive demand is large relative to average daily traded value and available free float.
- Expect elevated turnover and potential price strength during the pre-positioning window, but avoid extrapolating index-flow gains into long-term fundamental value.
- Monitor whether Meesho and Lenskart use improved liquidity and valuation support to pursue secondary sales, employee liquidity programs, acquisitions or additional capital raising.
- Reassess Biocon for technical selling pressure around the rebalance; any decline may create a fundamental entry point if the exclusion is flow-driven rather than earnings-driven.
- Track listed consumer-tech peers for sympathy moves, particularly companies that could become candidates for future global-index inclusion after meeting liquidity and free-float thresholds.